AstraZeneca PLC (AZN) Cash Flow Statement

The persistent OCF/NI ratio above 1.0, even reaching 2.03 in 2025Q3, suggests that reported earnings are backed by actual cash generation, likely due to significant non-cash D&A charges. This gap between net income and operating cash flow is a positive signal, indicating that accruals are not inflating earnings. Investors should monitor whether this trend persists as the company integrates recent acquisitions and faces potential IRA pricing pressures.

The wide range in FCF margins, from 6.9% in 2024Q1 to 22.4% in 2025Q3, indicates that quarterly FCF is not a reliable indicator of the company's cash generation capacity. The 2026Q2 FCF margin of 13.9% is closer to the historical average, suggesting a normalization after the 2025Q3 outlier. This volatility is likely driven by timing of working capital changes and capex, which investors should adjust for when assessing the underlying FCF trajectory.

The dramatic increase in capex to $3.1B in 2026Q2, compared to an average of ~$500M in previous quarters, suggests a major investment in manufacturing capacity or infrastructure, possibly to support the GLP-1 entry or rare disease expansion. This spike may be a one-time event, but if sustained, it could pressure near-term FCF. The low capital intensity in prior quarters (3-5% of revenue) is typical for pharma, but this outlier warrants monitoring to see if it signals a shift toward more asset-heavy operations.

The persistent negative working capital changes, except for a positive $835M in 2025Q3, suggest that AstraZeneca is using cash to fund receivables or inventory build-up, possibly ahead of product launches. The 2026Q2 negative change of -$433M is in line with the trend, but the volatility indicates that working capital is a significant source of cash flow variability. Investors should assess whether this reflects efficient payables management or a structural drag on cash conversion.

The consistent dividend payments, with a notable $3.3B in 2026Q1 and $3.0B in 2024Q1, reflect a commitment to shareholder returns, though the payout ratio appears high relative to net income. Acquisition outflows, including the $2.3B in 2024Q2, suggest ongoing M&A activity, likely to bolster the pipeline. The lack of significant buybacks, except for a small $198.8M in 2025Q4, indicates that management prioritizes dividends and M&A over share repurchases, which may limit flexibility for future large deals.